Particle Sciences, Inc. (PSI) has acquired exclusive rights to Lyotropics Therapeutics’ LyoCell patent portfolio. The LyoCell technology allows for the solubilization, stabilization, and delivery of a wide range of compounds, both small and large molecule.   Under the revenue-share agreement, PSI obtains a full license to the technology except for compounds previously developed by Lyotropics. Particle Sciences will offer the technology to clients looking to increase bioavailability or develop pa...